EC Number | Application | Comment | Organism |
---|---|---|---|
3.4.17.11 | drug development | enzyme is used in enzyme prodrug therapy to treat human breast cancer, the enzyme catalyzes the activation of the di- and trifluorinated prodrugs | Pseudomonas sp. |
3.4.17.11 | medicine | enzyme is used in enzyme prodrug therapy to treat human breast cancer, the enzyme catalyzes the activation of the di- and trifluorinated prodrugs | Pseudomonas sp. |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.17.11 | (4-[bis(2-chloroethyl)amino]-2,3,5,6-tetrafluorobenzoyl)-L-glutamic acid | prodrug, competitive inhibition | Pseudomonas sp. | |
3.4.17.11 | (4-[bis(2-iodoethyl)amino]-2,3,5,6-tetrafluorobenzoyl)-L-glutamic acid | prodrug, competitive inhibition | Pseudomonas sp. |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
3.4.17.11 | 0.0011 | - |
(4-[bis(2-bromoethyl)amino]-2,3,5-trifluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 0.0012 | - |
(4-[bis(2-bromoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 0.0017 | - |
(4-[bis(2-chloroethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 0.0017 | - |
(4-[bis(2-iodoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 0.0026 | - |
(4-[bis(2-chloroethyl)amino]-2,3,5-trifluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 0.0028 | - |
(4-[bis(2-iodoethyl)amino]-2,3,5-trifluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 0.0034 | - |
(2-chloroethyl)-(2-(methylsulfoyloxyethyl)amino)aminobenzyl-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
3.4.17.11 | Zn2+ | required | Pseudomonas sp. |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.17.11 | (4-[bis(2-bromoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid + H2O | Pseudomonas sp. | a difluorinated prodrug | 4-[bis(2-bromoethyl)amino]-3,5-difluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-bromoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid + H2O | Pseudomonas sp. RS16 | a difluorinated prodrug | 4-[bis(2-bromoethyl)amino]-3,5-difluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-iodoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid + H2O | Pseudomonas sp. | a difluorinated prodrug | 4-[bis(2-iodoethyl)amino]-3,5-difluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-iodoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid + H2O | Pseudomonas sp. RS16 | a difluorinated prodrug | 4-[bis(2-iodoethyl)amino]-3,5-difluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | additional information | Pseudomonas sp. | enzyme is used in enzyme prodrug therapy to treat human breast cancer, the enzyme catalyzes the activation of the di- and trifluorinated prodrugs, overview | ? | - |
? | |
3.4.17.11 | additional information | Pseudomonas sp. RS16 | enzyme is used in enzyme prodrug therapy to treat human breast cancer, the enzyme catalyzes the activation of the di- and trifluorinated prodrugs, overview | ? | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.17.11 | Pseudomonas sp. | - |
gene CPG2 | - |
3.4.17.11 | Pseudomonas sp. RS16 | - |
gene CPG2 | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.17.11 | (2-chloroethyl)-(2-(methylsulfoyloxyethyl)amino)aminobenzyl-L-glutamic acid + H2O | a prodrug | Pseudomonas sp. | (2-chloroethyl)-(2-(methylsulfoyloxyethyl)amino)aminobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-bromoethyl)amino]-2,3,5-trifluorobenzoyl)-L-glutamic acid + H2O | a trifluorinated prodrug | Pseudomonas sp. | 4-[bis(2-bromoethyl)amino]-2,3,5-trifluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-bromoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid + H2O | a difluorinated prodrug | Pseudomonas sp. | 4-[bis(2-bromoethyl)amino]-3,5-difluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-bromoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid + H2O | a difluorinated prodrug | Pseudomonas sp. RS16 | 4-[bis(2-bromoethyl)amino]-3,5-difluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-chloroethyl)amino]-2,3,5-trifluorobenzoyl)-L-glutamic acid + H2O | a trifluorinated prodrug | Pseudomonas sp. | 4-[bis(2-chloroethyl)amino]-2,3,5-trifluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-chloroethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid + H2O | a difluorinated prodrug | Pseudomonas sp. | 4-[bis(2-chloroethyl)amino]-3,5-difluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-iodoethyl)amino]-2,3,5-trifluorobenzoyl)-L-glutamic acid + H2O | a trifluorinated prodrug | Pseudomonas sp. | 4-[bis(2-iodoethyl)amino]-2,3,5-trifluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-iodoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid + H2O | a difluorinated prodrug | Pseudomonas sp. | 4-[bis(2-iodoethyl)amino]-3,5-difluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | (4-[bis(2-iodoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid + H2O | a difluorinated prodrug | Pseudomonas sp. RS16 | 4-[bis(2-iodoethyl)amino]-3,5-difluorobenzoic acid + L-glutamate | - |
? | |
3.4.17.11 | methotrexate + H2O | - |
Pseudomonas sp. | 4-[(2,4-diamino-6-(pteridinyl)methyl)-methylamino]-benzoic acid + L-glutamate | - |
? | |
3.4.17.11 | methotrexate + H2O | - |
Pseudomonas sp. RS16 | 4-[(2,4-diamino-6-(pteridinyl)methyl)-methylamino]-benzoic acid + L-glutamate | - |
? | |
3.4.17.11 | additional information | enzyme is used in enzyme prodrug therapy to treat human breast cancer, the enzyme catalyzes the activation of the di- and trifluorinated prodrugs, overview | Pseudomonas sp. | ? | - |
? | |
3.4.17.11 | additional information | half-lives of prodrugs and drugs, overview | Pseudomonas sp. | ? | - |
? | |
3.4.17.11 | additional information | enzyme is used in enzyme prodrug therapy to treat human breast cancer, the enzyme catalyzes the activation of the di- and trifluorinated prodrugs, overview | Pseudomonas sp. RS16 | ? | - |
? | |
3.4.17.11 | additional information | half-lives of prodrugs and drugs, overview | Pseudomonas sp. RS16 | ? | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.17.11 | carboxypeptidase G2 | - |
Pseudomonas sp. |
3.4.17.11 | CPG2 | - |
Pseudomonas sp. |
EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|---|
3.4.17.11 | 37 | - |
assay at | Pseudomonas sp. |
EC Number | Turnover Number Minimum [1/s] | Turnover Number Maximum [1/s] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
3.4.17.11 | 220 | - |
(4-[bis(2-iodoethyl)amino]-2,3,5-trifluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 583 | - |
(2-chloroethyl)-(2-(methylsulfoyloxyethyl)amino)aminobenzyl-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 732 | - |
(4-[bis(2-chloroethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 825 | - |
(4-[bis(2-bromoethyl)amino]-2,3,5-trifluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 827 | - |
(4-[bis(2-bromoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 1150 | - |
(4-[bis(2-iodoethyl)amino]-3,5-difluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. | |
3.4.17.11 | 1150 | - |
(4-[bis(2-chloroethyl)amino]-2,3,5-trifluorobenzoyl)-L-glutamic acid | pH 7.3, 37 °C | Pseudomonas sp. |
EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|---|
3.4.17.11 | 7.3 | - |
assay at | Pseudomonas sp. |